Doctors and scientists from the Institute of Cardiovascular and Medical Sciences will undertake the world’s first in-human trial of vagus nerve stimulation in stroke patients. Stroke can result in the loss of brain tissue and negatively affect various bodily functions from speech to movement, depending on the location of the stroke.
The study, which will be carried out at the Western Infirmary in Glasgow, will recruit 20 patients who suffered a stroke around six months ago and who have been left with poor arm function as a result.
Each participant will receive three one-hour sessions of intensive physiotherapy each week for six weeks to help improve their arm function.
Half of the group will also receive an implanted Vivistim device, a vagus nerve stimulator, which connects to the vagus nerve in the neck. When they are receiving physiotherapy to help improve their arm, the device will stimulate the nerve.
It is hoped that this will stimulate release of the brains own chemicals, called neurotransmitters, that will help the brain form new neural connections which might improve participants ability to use their arm.
Lead researcher Dr Jesse Dawson, a Stroke Specialist and Clinical Senior Lecturer in Medicine, said: “When the brain is damaged by stroke, important neural connections that control different parts of the body can be damaged which impairs function.
“Evidence from animal studies suggests that vagus nerve stimulation could cause the release of neurotransmitters which help facilitate neural plasticity and help people re-learn how to use their arms after stroke; particularly if stimulation is paired with specific tasks. A slightly different type of vagus nerve stimulation is already successfully used to manage conditions such as depression and epilepsy.
“This study is designed to provide evidence to support whether this is the case after stroke but our primary aim is to assess feasibility of vagus nerve stimulation after stroke.
“It remains to be seen how much we can improve function, but if we can help people perform even small actions again, like being able to hold a cup of tea, it would greatly improve their quality of life.”
The study is being sponsored by Dallas-based Microtransponder Inc, a medical device company that has developed the Vivistim device and has received substantial support for their work from the US National Institutes of Health. They are also exploring vagus nerve stimulation for the treatment of tinnitus.
Anyone interested in taking part in the study should contact: email@example.com or call 0141 211 2948.
For more information contact Stuart Forsyth in the University of Glasgow Media Relations Office on 0141 330 4831 or email firstname.lastname@example.org